ARS PHARMACEUTICALS INC
SPRYNASDAQTrading Snapshot
- Day Range
- $4.26 – $4.35
- 52-Week Range
- $4.00 – $13.15
- Volume
- $3.18B
- Avg Volume
- $2.44B
- Shares Outstanding
- 99.3M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $84M
- Last Q Revenue
- $34M
- P/E Ratio
- -2.0
- P/S Ratio
- 3.7x
- EPS (TTM)
- $-2.17
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.6%
Why Investors Own SPRY
- ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARS PHARMACEUTICALS INC
SPRY
StockOtter · stockotter.spaceAbout ARS PHARMACEUTICALS INC
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ARS PHARMACEUTICALS DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
New York, New York--(Newsfile Corp. - September 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and J
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that was never disclosed
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired securit
Kaplan Fox Notifies Investors: Deadline to Lead in the ARS Pharmaceuticals Inc. (SPRY) Securities Class Action is October 5, 2026
New York, New York--(Newsfile Corp. - September 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on beh
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to c
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
Eric Karas, ARS Pharmaceuticals' Chief Commercial Officer, is named as a defendant in a securities class action alleging investors were misled about the timing of expanded CVS Caremark coverage for neffy before SPRY shar